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Abstract
Purpose: To explore the expression pattern, prognostic value and functional role of miR-196b in glioblastoma (GBM)
patients using large cohorts.
Experimental Design: MiR-196b expression was measured using the Human v2.0 miRNA Expression BeadChip (Illumina) in
198 frozen glioma tissues. The expression levels of miR-196b were also validated in an independent cohort containing 128
formalin-fixed paraffin-embedded (FFPE) glioma samples using qRT-PCR. The presence of other molecular prognostic
indicators was assessed centrally in the glioma samples. Whole genome gene profiling was performed to investigate the
underlying biological behavior. MiR-196b functional analyses were performed in U87 and U251 cell lines.
Results: The expression levels of miR-196b were inversely correlated with overall survival in GBM patients. Gene set
enrichment analysis (GSEA) showed that the gene sets relating to cell cycle were significantly enriched in the cases with
miR-196b overexpression. Functional analyses in U87 and U251 cells revealed that miR-196b was involved in cell
proliferation.
Conclusions: MiR-196b is overexpressed and confers a poor prognosis via promoting cellular proliferation in GBM
patients.
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Introduction
Glioblastoma (GBM) is the most aggressive type of glioma.
Though there have been advances in therapy, the prognosis for
a GBM patient is still dismal, and the patients have a median
survival of only 14.6 months [1,2]. Furthermore, GBM patients
show remarkably different survival times from less than one week
to more than three years following diagnosis [3]. However, to date,
only the IDH1 mutation and G-CIMP signature have been
validated to predict prognosis across various studies [4,5].
MicroRNAs (miRNAs) belong to a recently discovered class of
small non-coding RNA molecules that regulate the expression of
multiple target genes and multiple cellular processes, including cell
differentiation, stem cell maintenance, and epithelial–mesenchy-
mal transition [6]. Beyond their involvement in a variety of
biological processes, miRNAs have also been found to participate
in processes involved in the molecular pathology of cancer [7].
Depending on the genes targeted, miRNAs can act either as
oncogenes or tumor suppressors [8]. It should be noted that
miRNAs are very stable molecules that can exist in FFPE samples
without degradation for a long period of time and can potentially
be specific prognostic markers to be used in clinic [9]. Recently,
some studies have identified that specific miRNA expression
signatures can provide insight into the diagnosis and prognosis of
a variety of human cancers [10–12]. It has been reported that
there is a relationship between miRNA expression and the
outcome of GBM patients [13]. However, to date, no stable
prognostic marker based on miRNA expression has been reported
in GBMs across various institutes.
Previous studies have shown contradictory conclusions re-
garding the expression patterns and prognostic values of miR-
196b in GBM patients [14,15]. Here, we report the expression
pattern of miR-196b using the expression values from micro-
arrays of 198 frozen glioma tissues. Furthermore, the expression
pattern and prognostic value of miR-196b were validated in an
independent cohort containing 128 FFPE samples. In addition,
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GBM samples were subjected to whole genome gene profiling.
Integrated analysis of miR-196b and whole genome gene
expression patterns showed that overexpression of miR-196b
was tightly correlated with the gene sets related to cell cycle.
Functional assays showed that miR-196b might serve as
a potential target for anti-proliferation therapies in GBM
patients.
Materials and Methods
Samples and Patients
All glioma samples included in our study were from the Chinese
glioma genome atlas (CGGA). The patients underwent surgical
resection between January 2006 and December 2009 and
subsequently received radiation therapy or alkylating agent-based
chemotherapy. Patients were eligible for the study if the diagnosis
of glioma was established histologically according to the 2007
WHO classification. Ten normal brain tissues were included. Of
them, seven normal adult brain samples were obtained after
informed consent from patients with severe traumatic brain injury
who needed post-trauma surgery and three other normal samples
were from patients who had undergone surgery for primary
epilepsy. This study was approved by the institutional review
boards of Beijing Tiantan Hospital and The First Affiliated
Hospital of Nanjing Medical University, and written informed
consent was obtained from all patients.
RNA Extraction
All of the tissue samples were immediately snap-frozen in liquid
nitrogen after surgery. A hematoxylin and eosin stained frozen
section was prepared for assessment of the percentage of tumor
cells before RNA extraction. Only samples with greater than 80%
tumor cells were selected. Total RNA from frozen tumor tissues
was extracted using the mirVana miRNA Isolation kit (Ambion,
Austin, TX, USA) according to the manufacturer’s protocol. RNA
concentration and quality were measured using the NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Houston,
TX, USA). MiRNAs of FFPE tissues were extracted using an
RNeasy FFPE Kit (QIAGEN).
MiR-196b Expression Analyses
MiR-196b expression values of 198 glioma tissues were from
Chinese Glioma Genome Atlas (CGGA), which is a database that
focuses on glioma. Briefly, 200 ng of total RNA was polyadeny-
lated and then reverse transcribed into to cDNA using a biotin-
labeled Oligo dT primer with a universal PCR sequence. After
cDNA synthesis, miRNAs were individually interrogated using
specific oligonucleotides. A single miRNA-specific Oligo (MSO)
was designed against each mature miRNA sequence, and miRNA-
specific primers were extended using DNA polymerase. Universal
primers were used to amplify the cDNA templates, and the primer
complimentary to the array was fluorescently labeled. Finally, the
labeled, single-stranded PCR products were hybridized to the
Human v2.0 miRNA Expression BeadChip (Illumina, Inc., San
Diego, CA, USA) with 1,146 human miRNAs (97% coverage of
the miRBase 12.0 database).
Whole Genome Gene Profiling
Microarray analysis was performed using the Agilent Whole
Human Genome Array according to the manufacturer’s instruc-
tions. The integrity of the total RNA was checked using an
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA). cDNA
and biotinylated cRNA were synthesized and hybridized to the
array. Data were acquired using the Agilent G2565BA Micro-
array Scanner System and Agilent Feature Extraction Software
(v9.1). Probe intensities were normalized using GeneSpring GX
11.0.
Immunohistochemistry
Immunohistochemistry was performed as described in the
previous report [16]. Briefly, surgical specimens were fixed in
formalin, routinely processed and paraffin embedded. Five-
micron-thick sections were prepared, and immunohistochemical
staining with streptavidin-biotin immunoperoxidase assay was
performed using antibodies against Ki-67. The staining intensity
was scored by two pathologists without knowledge of clinical
information on a scale of 0 to 3 (0, negative; 1, slight positive; 2,
moderate positive; 3, intense positive). A score of 0 and 1 or 2 and
3 indicated low or high expression, respectively. Controls without
primary antibody and positive control tissues were included in all
experiments to ensure the quality of staining.
Gene set Enrichment Analysis
To obtain more information about the biologic processes related
to miR-196b expression in GBM, we performed gene-expression
profiling using Agilent Whole Human Genome Array and GSEA
as described previously [17].
Cell Culture and Oligonucleotide Transfection
U87 and U251 glioma cells were purchased from the Chinese
Academy of Sciences Cell Bank. SHG44 cells were cultured in
DMEM culture medium supplemented with 10% fetal bovine
serum (FBS). All cells were maintained in a 37uC, 5% CO2
incubator and routinely passaged at two-to three-day intervals.
Cells from passages 2–4 were used in all experiments.
Oligonucleotide transfection was performed using mimics of
miR-196b and mimics negative control (NC) that were chemically
synthesized by Shanghai GenePharma Company (Shanghai,
China). Cells were transfected using LipofectAMINE 2000 reagent
(Invitrogen, Carlsbad, USA). Transfection complexes were pre-
pared according to the manufacturer’s instructions and added
directly to the glioma cells to result in a final oligonucleotide
concentration of 10 nmol/L. The transfection medium was
replaced 8 h post-transfection.
Cell Growth Assays
The MTT assay was used to determine relative cell growth.
U87 and U251 cells were plated at 10
4 cells per well in 96-well
plates with six replicate wells for each condition, transfected and
assayed 24 h and 48 h post-transfection. A cell growth assay was
performed using MTT (Sigma, St. Louis, MO) as described in ref
[18]. The cell viability was determined at 540 nm absorbance
using an enzyme-linked immunosorbent assay plate reader. All
data points represent the mean of a minimum of six wells.
Western Blotting Assays
As described in our previous report [19], to determine the levels
of E2F1 expression, total protein was isolated in lysis buffer
(137 mM NaCl, 15 mM EGTA, 15 mM MgCl2, 0.1 mM sodium
orthovanadate, 0.1% Triton X2100, 25 mM MOPS, 100 mM
phenylmethylsulfonyl fluoride, and 20 mM leupeptin, adjusted to
pH 7.2). Equal amounts of protein (30 mg) were loaded into the
sample wells and separated on a 12% sodium dodecyl sulfate-
polyacrylamide gel. The electrophoresed proteins were transferred
to a polyvinylidene difluoride Immobilon-P membrane (Millipore,
Watford, UK) and subjected to immunoblot analysis with the
miR-196b in Glioblastomas
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loading of the gel.
Cell Cycle Assay
U251 cells transfected with miR-196b and NC for 48 h were
collected, washed in phosphate-buffered saline (PBS), and fixed
with 70% cold ethanol for at least 1 h. After extensive washing, the
cells were suspended in HBSS containing propidium iodide
(69 mM; Sigma) and RNase A (0.1 mg/mL; Sigma), incubated for
1 h at room temperature, and analyzed by FACScan (Becton
Dickinson) [20].
Immunofluorescence
U251 cells transfected with miR-196b and NC for 48 h were
seeded on coverslips and fixed with 4% paraformaldehyde, treated
with3%H2O2for10 min,blockedfornonspecificstainingwith10%
bovineserumalbumin(Sigma-Aldrich)inPBSfor1 handincubated
with the Ki-67 antibody (1:40dilutions) overnight at 4 uC. TRITC-
conjugated Goat Anti-Mouse antibody (1:200 dilutions) was added
for2 hat37 uC.DAPIreagentwasusedtostaintheU251cellnuclei
and the cells were visualized using an immunofluorescence micro-
scope and analyzed using IPP5.1(Olympus).
Statistical Analysis
Kaplan-Meier survival analysis was used to estimate the survival
distributions, and the log-rank test was used to assess the statistical
significance between stratified survival groups using GraphPad
Prism 5.0 statistical software. Student’s t-tests, One-way ANOVA
and Exact Sig (2-sided) x2 test were performed using SPSS 13.0.
All data are presented as the means 6 SE. A two-sided P value of
,0.05 was considered significant.
Results
MiR-196b is Upregulated and Confers a Poor Prognosis of
GBM Patients
The expression of mature miR-196b was measured in a series of
198 glioma samples (63 low-grade gliomas, 44 anaplastic gliomas
and 91 GBMs) via microarrays. As shown in Figure 1A, GBMs
demonstrated a significant increase in miR-196b transcript levels
compared to the mean expression levels observed in low-grade
gliomas (p,0.01) or anaplastic gliomas (p,0.01). No significant
difference in miR-196b expression levels was observed between
low-grade and anaplastic gliomas (P=0.11). To further confirm
this result, we performed qRT-PCR to examine miR-196b levels
in an independent cohort containing 128 FFPE samples (30 low
Figure 1. The expression of miR-196b in gliomas and its association with survival in GBMs. (A) Expression patterns of miR-196b in the
microarray cohort containing 198 frozen glioma tissues. (B) Expression patterns of miR-196b in the validation cohort containing 128 glioma FFPE
glioma tissues. (C) Kaplan-Meier survival curves according to the expression of miR-196b in 91 frozen GBM tissues. (D) Kaplan-Meier survival curves
according to the expression of miR-196b in 68 FFPE GBM tissues. The log-rank test was used to calculate p values.
doi:10.1371/journal.pone.0038096.g001
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shown in Figure 1B, miR-196b was significantly upregulated in
GBMs compared to that of low-grade gliomas (p,0.01) or
anaplastic gliomas (p,0.01). No difference in miR-196b expres-
sion levels was observed between low-grade and anaplastic gliomas
(P=0.18). Furthermore, we found that the differential expression
of miR-196b between normal tissues and low grade and anaplastic
gliomas is not statistical significant (P=0.84 for low grade gliomas;
P=0.19 for anaplastic gliomas). However, normal tissues have
a significant lower of miR-196b when compared glioblastoma
tissues (P=0.01) (Figure S1). The correlation between miR-196b
expression and overall survival was measured through Kaplan-
Meier survival curve analysis with a log-rank comparison. GBM
samples expressing higher than median levels of miR-196b were
associated with decreased survival relative to those with miR-196b
levels lower than the median (p,0.01) in the microarray cohort
(Figure 1C). Further, miR-196b expression was inversely corre-
lated with overall survival in the 68 GBM samples of the
independent validation set (p,0.01) (Figure 1D). These results
also demonstrated that miR-196b was stable in FFPE slides and
might have potential for future clinic use.
MiR-196b is Tightly Associated with the Biological
Process of the Cell Cycle
To gain insights into the biologic processes related to miR-
196b expression in GBMs, sixty GBM samples with large
variability in miR-196b transcript levels were subjected to whole
genome gene profiling. A total of 1294 probes significantly
correlated (R.0.3 or ,20.3, P,0.01) with miR-196b expres-
sion levels (Figure 2; Table S1; 685 probes with positive
correlation and 609 with negative correlation).Arrows indicate
the genes that are discussed in the text. Gene set enrichment
analysis (GSEA) showed that the gene sets related to cell cycle
were significantly enriched in the cases with miR-196b over-
expression (Table 1). Using a p value of ,0.001, 23 biologic
processes mainly related to cell cycle, M phase, mitosis, and
chromosome segregation were significantly enriched in the
GBM samples with miR-196b overexpression. Furthermore, the
immunohistological staining of proliferation marker Ki-67 set
was performed in the 68 GBM samples of the independent
validation. A positive correlation of miR-196b and Ki-67 was
also found (Figure 3; Table 2).
Figure 2. Heatmapofthegene-expressionsignaturecorrelated
withmiR-196bexpression.Rowsrepresentedprobesetsandcolumns
representedpatients.Patientswereorderedfromlefttorightbyincreasing
miR-196bexpression.Expressionlevelsoftheprobesetswererepresented
by color, with green demonstrating expression less than and red
demonstrating expression greater than the median value for the given
probeset.Arrowsindicatedgenesthatwerediscussedin thetext.
doi:10.1371/journal.pone.0038096.g002
Table 1. Gene sets enriched in GBM samples with miR-196b overexpression.
NAME ES NES NOM p-val FDR q-val
CELL_CYCLE_PROCESS 20.47827 22.57053 0 0
CELL_CYCLE_PHASE 20.4891 22.55122 0 0
M_PHASE 20.5207 22.54711 0 0
MITOSIS 20.52103 22.46316 0 0
M_PHASE_OF_MITOTIC_CELL_CYCLE 20.52028 22.4344 0 0
MITOTIC_CELL_CYCLE 20.46339 22.41896 0 0
CELL_CYCLE_GO_0007049 20.40213 22.31263 0 8.40E-05
MITOTIC_SISTER_CHROMATID_SEGREGATION 20.70647 22.21738 0 4.91E-04
CHROMOSOME_SEGREGATION 20.56145 22.15355 0 9.87E-04
CHROMOSOME_ORGANIZATION_
AND_BIOGENESIS
20.43082 22.1452 0 9.98E-04
doi:10.1371/journal.pone.0038096.t001
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Proliferation in GBMs
To analyze the functional role of miR-196b in GBMs, we
overexpressed miR-196b using transient transfection in U87 and
U251 cells. Changes in cell proliferation were assessed at 24 and
48 h post-transfection. The U87 and U251 cells transfected with
miR-196b mimics showed increased cell proliferation rates
compared to those of mock-transfected cells (Figure 4A). Further
functional experiments were performed in U251 cells. As shown in
Figure 4B and Figure 4C, miR-196b could increase the fraction of
Ki267+U251 cells and S-phase proportion of U251 cells. Besides,
miR-196b could increase E2F1 expression at protein level in U251
cells (Figure 4D). These results indicated that miR-196b might be
a potential target for anti-proliferation therapy in GBMs.
Discussion
It has been reported that aberrant miRNA expression patterns
highly correlate with progression and prognosis in various cancers.
MiRNAs are very stable in FFPE tissues on slides, with no
degradation over a long period of time, and are thus a potential
diagnostic and prognostic tool in clinic [21]. In the present study,
we investigated the expression level of miR-196b in two
independent cohorts, totaling over 300 glioma patients. We
further showed that the expression level of miR-196b was
upregulated and conferred a poor prognosis in GBM patients.
Whole genome gene profiling was performed to investigate the
underlying biological behavior. MiR-196b functional analyses
were performed in U87 and U251 cell lines.
The expression pattern and functional role of miR-196b are
very controversial across various cancers. Several studies have
demonstrated that miR-196b functions as a tumor suppressor in
leukemia [22–26]. The expression of miR-196b has also been
reported to be significantly elevated in gastric cancer [27]. To
date, there are two articles that have reported the correlation of
miR-196b with prognosis in GBMs, but they draw opposite
conclusions. Guan et al. reported that miR-196 is overexpressed
and negatively correlated with OS [15]. However, the opposite
association between miR-196b and OS was reported in GBM
patients in another institute [14]. The numbers of GBM patients in
the above two studies was 39 and 38, respectively. The large
variability of results may be due to the small sample numbers.
Larger studies need to be performed to establish the expression
pattern and prognostic significance of miR-196b in GBM patients.
Here, we evaluated the expression of miR-196b in 198 frozen
glioma samples using microarray. Furthermore, we validated the
expression pattern of miR-196b in 128 glioma FFPE tissues. We
found that miR-196b was significantly overexpressed in GBMs
when compared with low-grade and anaplastic gliomas. However,
there is no significant difference in miR-196b levels between low
grade and anaplastic gliomas. Meanwhile, survival analysis
revealed that overexpression of miR-196b in 91 frozen GBM
samples conferred a poor prognosis. The prognostic value of miR-
196b was also validated in 68 FFPE GBM samples. These results
indicated that miR-196b might be involved in malignant pro-
gression and function as potential oncogene in GBMs.
To date, no study has been performed to investigate the
biological processes of miR-196b in GBMs systematically. In the
present study, sixty GBM samples with large variability in miR-
196b transcript levels were subjected to whole genome gene
profiling. We observed a negative correlation of miR-196b
Figure 3. Representative antibody stainings for Ki-67. IHC results of Ki-67 are shown on a scale of 0 to 3 (0, ,10% (A); 1, 10%–30% (B); 2, 30%–
60% (C); 3, .60% (D)). And scale of 0 and 1 and scale of 2 and 3 indicated low and high expression, respectively.
doi:10.1371/journal.pone.0038096.g003
Table 2. Correlation of miR-196b and Ki-67 expression.
High miR-196b Low miR-196b
High expression of Ki-67 protein 32 (47%) 17 (25%)
Low expression of Ki-67 protein 2 (3%) 17 (25%)
Pearson correlation: R=0.492, P,0.01.
doi:10.1371/journal.pone.0038096.t002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38096Figure 4. MiR-196b functions as an oncogene via promoting cell proliferations in glioma cells. (A) miR-196b could increased proliferation
in U87 and U251 cells. (B) miR-196b could increase the fraction of Ki-67+U251 cells. (C) miR-196b could increase S-Phase proportion in U251 cells. (D)
miR-196b could increase E2F1 expression at protein level in U251 cells. *p,0.05.
doi:10.1371/journal.pone.0038096.g004
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dingCSRP1, DBC1 and BIN1 [28–30]. Some oncogenes that
drive cell proliferation, including E2F1 and EZH2, were also
found to positively correlate with the expression of miR-196b
[31,32]. The proliferation marker Ki-67 also showed a positive
correlation with miR-196b expression. GSEA analysis showed that
the gene sets related to cell cycle were significantly enriched in the
cases with miR-196b overexpression. Further in vitro experiments
showed that the transfection of miR-196b mimics into glioma cells
could increase cell proliferation significantly. These results suggest
that miR-196b functions as an oncogene via promoting cell
proliferation in GBMs.
Our results show that miR-196b is overexpressed in GBMs and
confers poor prognosis based on large samples in both frozen and
FFPE samples. We also show that miR-196b is tightly associated
with cell cycle progression and that ectopic expression in GBM
cells could increase proliferation significantly. In summary, unlike
in other cancers, miR-196b is an oncogene and could be
a potential target for anti-proliferative therapy in GBMs.
Supporting Information
Figure S1 MiR-196b expression levels in 10 Normal
tissues, 15 low grade gliomas, 15 anaplastic gliomas and
15 glioblastomas were evaluated by real-time qRT-PCR.
And we found that the differential expression of miR-196b
between normal tissues and low grade and anaplastic gliomas is
not statistical significant (P=0.84 for low grade gliomas; P=0.19
for anaplastic gliomas). However, normal tissues have a significant
lower of miR-196b when compared Glioblastoma tissues
(P=0.01).
(TIF)
Table S1 A list of the 1294 probes that correlate with
expression of mir-196b.
(XLSX)
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